Project Grant R01AI192499
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $528K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- This $414,803 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Massachusetts Institute of Technology (MIT) to develop improved T cell receptor (TCR) engineering strategies for TCR-T cell cancer immunotherapy. The key products and services to be delivered under this grant include: Implementing high-throughput library screens of TCR constant region variants to identify mutations that can improve TCR signaling strength, with...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of "Next Generation Platforms for Interrogating TCR Specificity" at The Leland Stanford Junior University. The $368,294 award spanning 9/1/2025 to 8/31/2028 will optimize two complementary methods to identify, detect, and target peptide-MHC tumor antigens. This includes improving a yeast peptide-MHC display platform to discover new tumor...
- This $300,002 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research at Baylor University to develop an innovative artificial intelligence (AI)-driven approach for accelerating the discovery of dual-targeted cancer theranostic agents. The research aims to develop bispecific small molecule inhibitory conjugates (BSMICs) targeting two critical enzymes in cancer cell fatty acid metabolism - stearoyl-CoA desaturase-1...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded Nightstar Biotechnologies, Inc. a $360,442 Project Grant to develop an artificial intelligence (AI) platform called PMTNET for designing optimal therapeutic T-cell receptor (TCR-T) cells to treat cholangiocarcinoma (CCA). The PMTNET platform aims to address the challenges in traditional TCR-T cell design by predicting TCR-antigen interactions to enable targeting of minimally expressed tumor antigens while avoiding...
- The University of Texas MD Anderson Cancer Center received a $539,453 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop a microfluidics-based approach for isolating antigen-specific T cells in non-small cell lung cancer. The research aims to optimize methods for enriching and identifying T cells that recognize and bind to tumor cells, leveraging this platform to predict clinical outcomes. As a sub-award, the...
- This $177,180 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Fred Hutchinson Cancer Center in Seattle, Washington supports research to improve engineered TCR-T cell therapy for solid tumors. The key goals are to investigate whether engineered TCR-T cells form PD-1+TCF1+ stem-like progenitor exhausted T cell populations in tumor-draining lymph nodes, similar to endogenous tumor-specific T cells. This could impact the long-term persistence...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Pumpkinseed Technologies Inc. for $353,204 supports the development and demonstration of a novel technology called Cell-MAPP. The goal of this Phase I SBIR project is to create the first system capable of continuously monitoring the state transitions of individual T cells in response to antigen exposure. Cell-MAPP will utilize antigen-multimer barcoding and single-cell TCR sequencing to connect...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies" at the University of Texas MD Anderson Cancer Center in Houston, TX. The $505,071 award, made on February 15, 2025, will fund research aimed at identifying new cancer-specific antigens and developing innovative T cell-based immunotherapies...
- The National Cancer Institute awarded a $421,685 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Biology Research Federal Grant Program (CFDA 93.396). The grant supports a research project titled "Pan-Cancer Analysis of Convergent Immunoglobulins from Tumor-Infiltrating B Cells" with an award period from August 1, 2025 to July 31, 2027. The project aims to analyze immunoglobulins from different cancer types in the TCGA database, identify convergent...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...